FDA Report on Postmarketing Requirements for Drug and Biologics Firms

Summary

The FDA is required to annually report on the status of postmarketing requirements and commitments for approved drug and biologics products under the FDAMA, which includes studies and clinical trials agreed upon by applicants or required by the FDA.